We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Simple Blood Test Diagnoses Bipolar Disorder More Accurately

By LabMedica International staff writers
Posted on 26 Oct 2023
Print article
Image: The blood test offers a new way of improving diagnosis of bipolar disorder (Photo courtesy of 123RF)
Image: The blood test offers a new way of improving diagnosis of bipolar disorder (Photo courtesy of 123RF)

Bipolar disorder is a condition that affects about 1% of the global population, which translates to roughly 80 million people. However, nearly 40% of those affected are incorrectly diagnosed with major depressive disorder, a condition that requires a different treatment approach. Incorrectly treating bipolar disorder with antidepressants without the use of mood stabilizers can induce a manic episode. Currently, a comprehensive psychiatric evaluation is the most reliable method for diagnosing bipolar disorder, but these assessments often have long waiting times and are time-consuming. Now, a simple blood test with the ability to diagnose bipolar disorder could ensure that patients receive the right treatment the first time and also reduce the strain on healthcare providers.

Researchers at the University of Cambridge (Cambridge, UK) have created a novel diagnostic approach that employs a simple blood test to identify biomarkers linked to bipolar disorder. By combining an online psychiatric evaluation with the blood test, the team managed to correctly diagnose several patients who were previously misdiagnosed with major depressive disorder. On its own, the blood test could accurately diagnose bipolar disorder in up to 30% of patients. However, its efficacy improved notably when used alongside a digital mental health assessment. The inclusion of biomarker tests could assist doctors in distinguishing between major depressive disorder and bipolar disorder, conditions that exhibit similar symptoms but necessitate different drug treatments.

For their research, the team relied on samples and information gathered from the Delta study, which took place in the UK from 2018 to 2020. The study aimed to identify bipolar disorder among patients who had been diagnosed with major depressive disorder in the last five years and were currently experiencing depressive symptoms. The participants, who numbered over 3000, were enlisted online and completed an extensive online mental health questionnaire containing over 600 questions. Topics covered by the questionnaire included past and present depressive episodes, generalized anxiety, symptoms of mania, family history, and substance abuse. Out of those, around 1000 participants were chosen to provide a dried blood sample through a finger prick. The samples were then analyzed for over 600 different metabolites using mass spectrometry. After completing a thorough and validated diagnostic tool, the Composite International Diagnostic Interview, 241 participants were finally selected for the study.

Upon analyzing the data, the researchers identified a significant biomarker signal for bipolar disorder that was evident even after adjusting for variables like medication. Validation was performed on a separate group of patients who were clinically diagnosed with either major depressive disorder or bipolar disorder during the study's one-year follow-up. The combination of self-reported data and the biomarker test showed a significant enhancement in diagnosing bipolar disorder, particularly in cases where the diagnosis was not immediately evident. While the blood test is still in the proof-of-concept stage, the researchers believe it could serve as a valuable adjunct to existing diagnostic methods and may shed light on the biological origins of mental health disorders.

“The online assessment was more effective overall, but the biomarker test performs well and is much faster,” said Professor Sabine Bahn, who led the research. “A combination of both approaches would be ideal, as they’re complementary. In addition to the diagnostic capabilities of biomarkers, they could also be used to identify potential drug targets for mood disorders, which could lead to better treatments.”

Related Links:
University of Cambridge 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more

Pathology

view channel
Image: The new AI tool can help beat brain tumors (Photo courtesy of Crystal Light/Shutterstock)

New AI Tool Classifies Brain Tumors More Quickly and Accurately

Precision in diagnosing and categorizing tumors is essential for delivering effective treatment to patients. Currently, the gold standard for identifying various types of brain tumors involves DNA methylation-based... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.